Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Expectations By $0.01 EPS

Key Points

• Spero Therapeutics reported a quarterly loss of $0.16 per share, beating analyst expectations by $0.01. The company posted a 24.90% net margin and 35.58% return on equity.
• Shares fell 3.3% to $1.19, near the company’s 52-week low of $1.08. Analysts maintain a consensus “Reduce” rating, with one Hold and one Sell rating.
• Institutional ownership stands at 25.6%, with several investment firms recently establishing new positions. Spero is developing antibiotic therapies for multidrug-resistant infections, including lead candidate tebipenem HBr.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01, FiscalAI reports. Spero Therapeutics had a net margin of 24.90% and a return on equity of 35.58%.

Spero Therapeutics Trading Down 3.3%

NASDAQ SPRO traded down $0.04 on Wednesday, hitting $1.19. 764,858 shares of the company traded hands, compared to its average volume of 874,169. The business's 50 day moving average price is $1.93 and its 200-day moving average price is $2.30. Spero Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.08. The company has a market capitalization of $68.90 million, a price-to-earnings ratio of 4.96 and a beta of 1.55.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SPRO. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Spero Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut Spero Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Reduce".

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Invesco Ltd. bought a new position in shares of Spero Therapeutics during the 2nd quarter valued at approximately $43,000. Dimensional Fund Advisors LP bought a new stake in Spero Therapeutics during the 3rd quarter worth approximately $55,000. Millennium Management LLC bought a new stake in Spero Therapeutics during the 4th quarter worth approximately $56,000. Quadrature Capital Ltd purchased a new position in Spero Therapeutics during the fourth quarter valued at approximately $88,000. Finally, Two Sigma Investments LP purchased a new position in Spero Therapeutics during the third quarter valued at approximately $93,000. Institutional investors own 25.60% of the company's stock.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source